Proteomics in graft-versushost disease and graftversus-leukemia - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 459

Table 19.1B Candidate Acute GVHD Biomarkers with Diagnostic and Prognostic Significance Identified with Proteomics
Discovery

No. of
Patients in
Study

Biofluid
Source

Target
Organ Protein Reference Methods Diagnosis Prognosis Predictive

Peptides
set

[24] Urine CE-MS 35 Systemic ND ND Yes

[16] Serum SELDI-TOF 34 Systemic Yes ND ND

[17] Saliva SELDI-TOF

2D-DIGE
ELISA

41 Systemic ND ND Yes

[70] Urine CE-MS 33+ 141 * Systemic ND ND Yes

Proteins
set

[20] Plasma 3D-DIGE-MS 9 Systemic ND ND Yes

Albumin [24] Urine CE-MS 35 Systemic ND ND Yes

[17] Saliva SELDI-TOF

2D-DIGE
ELISA

41 Systemic ND ND Yes

465

CCL8 [61] Serum SELDI-TOF

ELISA

14 Systemic Yes ND ND

Collagen
α 1

[70] Urine CE-MS 33+ 141 * Systemic ND ND Yes

Cystatin [17] Saliva SELDI-TOF

2D-DIGE
ELISA

41 Systemic ND ND Yes

Elafin [23] Plasma LC-MS/MS

ELISA

20+ 492 * Skin Yes Yes ND

HGF [12] (in a

panel)

Plasma Antibody

microarrays
followed by
ELISA

42+ 282 * +
142 *

Sys-
temic/GI
tract

Yes Yes ND

IL-2R α [12] (in a

panel)

Plasma Antibody

microarrays
followed by
ELISA

42+ 282 * +
142 *

Systemic Yes Yes ND

IL-8 [12] Plasma Antibody

microarrays
followed by
ELISA

42+ 282 * +
142 *

Systemic Yes Yes ND

Lactofer-
rin

[17] Saliva SELDI-TOF

2D-DIGE
ELISA

41 Systemic ND ND Yes

Leukot-
riene A4
hydro-
lase

[24] Urine CE-MS 35 Systemic ND ND Yes

REG3 α [22] Plasma LC-MS/MS

ELISA

20+ 871 * +
143 *

GI tract Yes Yes ND

(Continued)